<div id="readability-page-1"><div><p>Danish pharmaceutical company Genmab has finalized its offer for all outstanding common shares in Merus. With this acquisition, the drug candidate petosemtamab, which holds two Breakthrough Therapy Designations, is now part of Genmab's portfolio.</p><p>  Genmab anticipates that petosemtamab will have a positive impact on EBITDA, projecting an annual sales potential of at least $1 billion through 2029, and subsequently, an annual revenue potential in the multi-billion dollar range.</p><p>  &#34;We are energized by the potential of petosemtamab to make a difference for patients with head and neck cancer,&#34; said CEO Jan van de Winkel in a press release.</p><p>Genmab now controls a total of 94.2 percent of Merus and has decided to give shareholders another opportunity to accept the offer by extending the acceptance period by ten trading days, until December 29. The offered price remains at $97 per share.</p></div></div>

MRUS

GMAB

<p>Genmab 已完成对 Merus 的收购，将癌症治疗药物 petosemtamab 纳入其产品组合。petosemtamab 获得了两个突破性疗法认证，预计将对 EBITDA 产生积极影响，并在 2029 年前实现至少 10 亿美元的年销售额。Genmab 现在控制了 Merus 的 94.2%，并将要约接受期限延长至 12 月 29 日，维持每股 97 美元的价格</p>

Genmab 完成对 Merus 的收购，借助新的癌症治疗方案增强其产品组合